Monkeypox

September 26, 2022

What is Monkeypox?

Though the COVID-19 pandemic has yet to completely subside, we are currently in the midst of another

government declared emergency due to Monkeypox. The first confirmed case in the U.S. was in May 2022. As of

September 14, 2022, a total of 23,117 cases have been reported and the number keeps growing.1 As a result, the

government declared Monkeypox an emergency in August 2022.


What is Monkeypox?

Monkeypox is a disease caused by the monkeypox virus. This virus is part of the same family as smallpox, but

less fatal.


How does Monkeypox spread?

Monkeypox is spread from person-to-person by close contact of the skin, which includes touching a shared

object, hugging, kissing, and sexual contact.2


What can I do to prevent Monkeypox?

Monkeypox is spread through close contact with infected persons. Everyone should be mindful of activities that

involve large crowds and avoid close contact with individuals that may be infected.


Can I prevent Monkeypox by getting the vaccine?

There are two (2) Monkeypox vaccines available, one is called JYNNEOS and the other is ACAM2000. These

vaccines are extremely limited due to the large number of cases in such a short timeframe. If there has been

close contact with someone with Monkeypox and you think there is a risk of getting infected, contact your

doctor to see if the vaccine is an option. Due to the limited availability of the vaccine, your doctor may refer you

to the local health department.


What happens if I get Monkeypox?

People with the Monkeypox infection present with a rash on the area that was in contact with the virus, which

may include hands, feet, face, chest, and genitals. Other symptoms may include fever, chills, exhaustion, and

muscle aches, which may resemble flu-like symptoms. From start to finish, the symptoms generally appear three

(3) weeks after exposure and will last about two (2) to four (4) weeks.


What can I do if I get Monkeypox?

There are no FDA approved drugs for Monkeypox. However, there is a drug used to treat smallpox that can be

used in severely ill Monkeypox patients called tecovirimat (TPOXX). Similar to the Monkeypox vaccine, the

treatment is very limited and should only be used in patients with severe symptoms or those at high-risk for

severe disease (i.e. people with a weakened immune system, children, pregnancy, etc.)3


In conclusion, Monkeypox has been declared an emergency with an increasing number of cases. Due to its

ability to spread through close skin contact and delay in the presentation of symptoms, many cases go

unnoticed. However, there are options to prevent the spread of Monkeypox with lifestyle modifications (e.g.

safe sex and avoiding close contact with infected persons) and vaccination, if applicable. If your healthcare

provider thinks you have Monkeypox and are at high risk, then treatment options are available.

If you have any questions, please contact your healthcare provider.


References:

1 2022 Outbreak Cases and Data. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID),

Division of High-Consequence Pathogens and Pathology (DHCPP). August 22, 2022

2 Prevention. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-

Consequence Pathogens and Pathology (DHCPP). August 22, 2022

3 Treatment Information for Healthcare Professionals. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious

Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP). August 22, 2022

A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: